Starling Registry Study
Completed · NCT04648293
Conditions: Hemodynamic Monitoring
At a glance
- Research payments reported, 2025
- $26,417
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 1,207
About the trial
- Sponsor
- Baxter Healthcare Corporation
- Tested
- Starling (device)
- Dates
- Started 2020-11-16; completion 2024-02-21
- Results posted
- Not yet
Hemodynamic optimization of critically ill patients is a goal for clinicians in order to afford the patient the best possible outcomes. Being able to precisely and rapidly determine patient fluid responsiveness provides the bedside physician and nursing staff the information needed to make critical decisions in regards to the patient's fluid status and management of additional fluids and medications. As fluid management and cardiac output determination are linked to better decision-making and improved outcomes in ICU, the use of a dynamic assessment of fluid responsiveness becomes a key tool for patient management. This study is designed to collect treatment and outcome data on patients t…
From ClinicalTrials.gov, last updated 2024-04-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Baxter Healthcare reported $26,417 in research payments for this study in 2025 (3 payments).
Products named: Starling System
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.